Drug shortages are an increasing worldwide problem that cause numerous difficulties for prescribers, pharmacists, patients, and federal regulators. Drug shortages also significantly burden health care finances and personnel.1
This week the FDA reported a shortage of 65 different medicines and shortage of another 42 medicines only just been resolved.2 This situation is similar for European countries; over the last year almost 300 medicines have been discontinued or temporarily not been available.3
Fagron’s products and services can assist in overcoming drug shortages and discontinuation for both sterile and non-sterile medicines. Just one example on how Fagron can help to cope with this problem, is ranitidine in SyrSpend® SF for patients with duodenal ulcer disease in Belgium. This compounded product has a proven physical-chemical stability of 58 days and is very suitable to replace the absent Zantac® oral syrup.
- C. Lee Ventola, The Drug Shortage Crisis in the United States - Causes, Impact, and Management Strategies. P&T. 2011.36: 740-742.
- http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm. Accessed on the 3th of February 2016.
- https://www.farmanco.knmp.nl. Accessed on the 3th of February 2016.